

Cover Story
FreeHealth Equity
By Matthew Bin Han Ong
FDA watchers and clinical trialists in oncology may want to pay close attention to the agency’s latest plans to increase representation of traditionally marginalized populations in drug development.
In Brief


Clinical Roundup


Trending Stories
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- In the Headlines: Is oncology ready to move away from animal testing?
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- Imaging’s ride to the bottom in clinical trials—and why it matters now
- Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya - Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out